GSK says its experimental targeted cancer therapy “Mo-rez” could become a blockbuster after early trial data showed strong results in hard-to-treat cancers. The drug demonstrated significant tumor shrinkage in patients with advanced ovarian and endometrial cancers, with over 60% of participants achieving at least a 30% reduction in tumor size. The promising data provide a
